Safety Study of Autologous Stem Cell in Liver Cirrhosis

Phase 2TerminatedNCT00382278

Universidade Federal do Rio de Janeiro15 enrolled

Overview

It is a fase I/II clinical study to evaluate feasibility, safety and kinetics of cellular therapy with bone marrow-derived mononuclear cells (ABMMC) in patients with liver cirrhosis. All the patients have moderate liver disfunction and a waiting time expectancy of liver transplantation longer than 12 months due their low MELD score. The ABMMC are labeled with 99mTc and infused through the hepatic artery. Scintigraphy is performed 2 and 24 hours after infusion. Patients are submitted to frequent clinical, laboratorial and image evaluation during the follow up period of 12 months.

A one year clinical trial was conducted. Patients had moderate liver dysfunction and a liver transplant was not expected to occur earlier than 12 months, due to low MELD scores. Hepatocellular carcinoma (HCC) and hepatic artery or portal vein thrombosis were excluded by color Doppler ultrasonography (DUS) and 3-phase computed tomography (CT). Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. ABMMC were delivered preferentially in the common hepatic artery by celiac trunk catheterism. Total body scintigraphy (TBS) was performed 3 hours after infusion. Patients were submitted to frequent clinical, biochemical and imaging evaluation during follow up.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Liver Cirrhosis

Interventions

Autologous bone marrow-derived mononuclear cells infusionPROCEDURE

Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Liver cirrhosis of any origin * Moderate liver disfunction (Child-Pugh Score=7-10) Exclusion Criteria: * Waiting time expectancy of liver transplant shorter than 12 months * Ongoing hepatic encephalopathy * Clinically detectable ascitis * Severe coagulation disorder (INR\>2,0 or platelets count \< 40.000) * Diagnosis or strong suspicion of cancer (except basocellular) * Pregnancy or intention to become pregnant during the next 12 months * Moderate or severe co-morbidity * Current participation in another clinical trial

Locations (1)

Hospital Universitário Clementino Fraga Filho

Rio de Janeiro, Rio de Janeiro, Brazil

Outcomes

Primary Outcomes

Changes in liver function according to Child-Pugh and MELD scores

Time frame: in days 1,2,7,14,30, 45, 60, 90, 120, 150, 180, 270, 360

Hepatic artery and portal vein thrombosis (doppler ultrasound)

Time frame: in days 1,2,7,14,90, 180 and 360

Development of liver nodule (ultrasound screening)

Time frame: in days 1,2,7,14,90, 180 and 360 (US) and in day 360 (CT scan )

Liver related mortality

Time frame: 360 days

Secondary Outcomes

Body distribution of 99mTc labeled BMDMC (scintigraphy)

Time frame: after 3 hours of infusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.